Arvinas shares have settled into a range around $6.77 in mid-November 2026, a relatively modest pullback of about 2.9% over the last 30 days. That short-term stability masks a longer downtrend: the stock stood near $9.20 in mid-August and has declined roughly 26% over the trailing quarter as investors shifted focus from the completed VEPPANU approval toward the execution risk embedded in an early-stage pipeline.
Within the last month, the stock has traded between roughly $6.33 and $8.03, with notable intraday swings around the company's third-quarter earnings report. As a clinical-stage biotechnology company, Arvinas carries little near-term revenue, so price action remains tightly linked to clinical data milestones, regulatory updates, and capital-allocation signals rather than traditional earnings fundamentals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Arvinas, Inc. is a New Haven, Connecticut-based clinical-stage biopharmaceutical company that pioneered PROTAC (PROteolysis TArgeting Chimera) protein degradation. The platform engineers small molecules that harness the body's natural protein-disposal system to selectively degrade disease-causing proteins, rather than merely inhibiting them.
The company's most advanced asset is VEPPANU (vepdegestrant), an oral estrogen-receptor degrader developed with PFE. It is the first and only FDA-approved PROTAC, cleared for adults with ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer. The rest of the pipeline spans oncology and neuroscience, including ARV-393 (a BCL6 degrader for lymphoma), ARV-027 (a polyQ-androgen-receptor degrader for spinal and bulbar muscular atrophy), ARV-102 (an LRRK2 degrader for neurodegenerative disease), ARV-6723 (an HPK1 degrader in immuno-oncology), and ARV-806 (a KRAS G12D degrader). Investors follow the stock primarily for its scientific platform and binary clinical catalysts rather than current revenue.
The defining event of 2026 was the May 1 FDA approval of VEPPANU, ahead of its assigned PDUFA date, marking the first commercial validation of the PROTAC modality. Shortly after, Arvinas and Pfizer licensed global rights to RIGL, shifting commercialization to Rigel while Arvinas refocused capital on its wholly owned Phase 1 programs.
On November 3, 2026, Arvinas reported third-quarter results showing a net loss of $53.9 million, or $0.82 per share, with revenue of just $0.5 million tied to the first royalty under the Rigel license. Cash, equivalents, and marketable securities totaled $558.9 million, funding operations into the second half of 2028. Management reiterated plans to disclose initial ARV-393 monotherapy data at the ASH conference in December, while noting that ARV-806 will advance only through a partner and that the U.S. IND for ARV-102 remains on hold, with the Phase 1b trial now prioritized in the EU and UK. From what I see, the cash position provides a solid buffer for upcoming readouts.
The remainder of 2026 and 2027 will be shaped by a series of clinical data disclosures. The initial ARV-393 dose-escalation readout at ASH in December 2026 is the nearest major catalyst, though it will focus on T-cell lymphoma patients dosed below predicted efficacious exposure levels. A fuller B-cell dataset, including glofitamab combination data, is expected in mid-2027.
Investors should also monitor initial ARV-027 healthy-volunteer data and ARV-6723 monotherapy data, the regulatory path for ARV-102 in Europe, and any partnering outcome for ARV-806. Broader risks include clinical execution, regulatory holds, competition in the protein-degradation space, and the eventual financing needs of the SBMA program, which extends beyond the current cash runway. As a clinical-stage company, Arvinas' valuation will remain sensitive to data quality and capital-allocation discipline. I’m watching this closely as the data readouts approach.
In my research process, I often turn to Tickeron’s Trending AI Robots to get a sense of automated strategies applied across the broader market. The platform highlights top-performing bots that cover various timeframes and styles, allowing me to cross-check signals alongside fundamental clinical updates for names like Arvinas. This adds a useful data-driven layer without replacing core due diligence on pipeline milestones.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARVN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 41 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 55 cases where ARVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +7.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.592). P/E Ratio (21.367) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapies to degrade disease-causing proteins
Industry Biotechnology